Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates
Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates
复制标题
DOI：
10.1016/j.bone.2007.06.004
复制
发表时间：
2007-09-01
期刊：
影响因子：
4.1
通讯作者：
Delmas, P. D.
中科院分区：
文献类型：
--
作者：
Confavreux, C. B.;Fontana, A.;Delmas, P. D.
芳香酶抑制剂在绝经后妇女早期乳腺癌的辅助治疗中显示出优于他莫昔芬的优势，但与骨折风险增加有关。本研究的目的是分析接受阿那曲唑治疗的绝经后妇女的骨丢失、骨转换及其决定因素。我们在118名接受阿那曲唑治疗的早期激素依赖型乳腺癌绝经后妇女的前瞻性开放队列研究中，调查了骨丢失和骨转换标志物(BTM)。没有接受骨质疏松症治疗的女性与114名年龄匹配的健康女性对照组进行了比较。骨质疏松症患者(T-Score
Aromatase inhibitors have demonstrated their superiority to tamoxifen as adjuvant therapy for early breast cancer in postmenopausal women, but are associated with an increased risk of fractures. The aim of our study was to analyze bone loss, bone turnover and their determinants in postmenopausal women treated with anastrozole.We investigated bone loss and bone turnover markers (BTM) in a prospective open cohort study of 118 postmenopausal women treated with anastrozole for an early hormone-dependent breast cancer. Women without osteoporosis were not treated and compared with an age-matched control group of 114 healthy women. Osteoporotic patients (T-score